Retronectin-induced T cell therapy - Takara Bio

Drug Profile

Retronectin-induced T cell therapy - Takara Bio

Alternative Names: Cancer immunity reconstruction therapy; Cell-based cancer immunotherapy

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takara Bio
  • Developer Kyoto Prefectural University of Medicine; Takara Bio; Tianjin Medical University Cancer Institute and Hospital
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lung-cancer(Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top